Nuclear factor-erythroid 2 related factor 2 (NRF2) biosensors and modulators of NRF2

Patent metadata

Field	Value
Publication number	US-10054583-B2
Application number	US-201314435000-A
Country	US
Kind code	B2
Filing date	Oct 9, 2013
Priority date	Oct 10, 2012
Publication date	Aug 21, 2018
Grant date	Aug 21, 2018

Abstract

Compositions include nucleic acid sequences encoding the C-terminal fragment of fragment (Seg3) of Nuclear factor-erythroid 2 related factor 2 (Nrf2). These compositions provide a target for identification of novel therapeutics having the ability to modulate the translation of Nrf2. Methods of treating subjects are also provided.

First claim

What is claimed:

1. A method of screening for an agent that modulates the translation of Nuclear factor-erythroid 2 related factor 2 (Nrf2), the method comprising:
a) providing a mammalian cell expressing a biosensor, wherein the biosensor comprises a nucleic acid encoding a reporter gene having a 5′ end and a 3′ end, wherein the nucleic acid encoding the reporter gene is fused at the 3′ end to a linker nucleic acid comprising at least one stop codon and having a 5′ end and a 3′ end, and wherein the linker is fused at the 3′ end to a nucleic acid encoding a C-terminal fragment of Nuclear factor-erythroid 2 related factor 2 (Nrf2) and wherein the nucleic acid encoding the C-terminal fragment of Nuclear factor-erythroid 2 related factor 2 (Nrf2) is SEQ ID NO: 2;
b) contacting the mammalian cell with an agent;
c) measuring the expression of the reporter gene; and
d) comparing the measured level of expression of the reporter gene to a measured level of expression in a control mammalian cell comprising the biosensor in the absence of the agent, wherein an increase in reporter gene expression in the presence of the agent indicates that the agent modulates the translation of Nuclear factor-erythroid 2 related factor 2 (Nrf2).

2. The method of claim 1 , wherein the reporter gene encodes luciferase, green fluorescent protein, red fluorescent protein, yellow fluorescent protein, cyan fluorescent protein, alkaline phosphatase, beta galactosidase, beta glucuronidase, chloramphenicol acetyltransferase, horseradish peroxidase, acetohydroxyacid synthase, nopaline synthase, or octopine synthase.

3. The method of claim 1 , wherein the reporter gene encodes a luciferase.

4. The method of claim 1 , wherein the reporter gene encodes a green fluorescent protein.

5. The method of claim 1 , wherein the measuring step comprises a luminescence assay, a chemiluminescence assay, a fluorescence assay or an enzymatic assay.

6. A method of screening for an agent that modulates the translation of Nuclear factor-erythroid 2 related factor 2 (Nrf2), the method comprising:
a) providing a mammalian cell expressing a biosensor according to SEQ ID NO: 3, which comprises a nucleic acid sequence encoding a luciferase gene, a linker nucleic acid comprising a stop codon, and a nucleic acid sequence encoding a C-terminal fragment of Nuclear factor-erythroid 2 related factor 2 (Nrf2);
b) contacting the mammalian cell with an agent;
c) measuring the expression of luciferase; and
d) comparing the measured level of expression of luciferase to a measured level of expression in a control mammalian cell comprising the biosensor in the absence of the agent, wherein an increase in luciferase expression in the presence of the agent indicates that the agent modulates the translation of Nuclear factor-erythroid 2 related factor 2 (Nrf2).

Assignees

• Univ Temple

Inventors

• Perez-Leal Oscar M
• Merali Salim
• Barrero Carlos A

Classifications

• C07K14/4701

  not used · CPC title

• A61K31/225

  Polycarboxylic acids · CPC title

• A61K31/353

  3,4-Dihydrobenzopyrans, e.g. chroman, catechin · CPC title

• A61K31/136

  having the amino group directly attached to the aromatic ring, e.g. benzeneamine · CPC title

• C12Q1/6883 Primary

  for diseases caused by alterations of genetic material · CPC title